How to buy Sarepta Therapeutics stock

Sarepta Therapeutics, Inc is a biotechnology business based in the US. Sarepta Therapeutics shares (SRPT) are listed on the NASDAQ and all prices are listed in US Dollars. Sarepta Therapeutics employs 866 staff and has a trailing 12-month revenue of around 0.00.

Sarepta Therapeutics share price

Use our graph to track the performance of SRPT stocks over time.

Sarepta Therapeutics shares at a glance

• Key figures

Information last updated 2021-04-23.

52-week range	$68.04 - $181.83
50-day moving average	$77.24
200-day moving average	$115.34
Wall St. target price	$134.47
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-8.14

Buy Sarepta Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Sarepta Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Sarepta Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Sarepta Therapeutics under- or over-valued?

Valuing Sarepta Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sarepta Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Sarepta Therapeutics's PEG ratio

Sarepta Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 159.25. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Sarepta Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Sarepta Therapeutics financials

Revenue TTM	$540.1 million
Gross profit TTM	$-245,526,000
Return on assets TTM	-14.67%
Return on equity TTM	-70.15%
Profit margin	-102.6%
Book value	$9.60
Market capitalisation	$5.7 billion

TTM: trailing 12 months

Shorting Sarepta Therapeutics shares

There are currently 7.3 million Sarepta Therapeutics shares held short by investors – that's known as Sarepta Therapeutics's "short interest". This figure is 7.4% up from 6.8 million last month.

There are a few different ways that this level of interest in shorting Sarepta Therapeutics shares can be evaluated.

Sarepta Therapeutics's "short interest ratio" (SIR)

Sarepta Therapeutics's "short interest ratio" (SIR) is the quantity of Sarepta Therapeutics shares currently shorted divided by the average quantity of Sarepta Therapeutics shares traded daily (recently around 1.2 million). Sarepta Therapeutics's SIR currently stands at 6.33. In other words for every 100,000 Sarepta Therapeutics shares traded daily on the market, roughly 6330 shares are currently held short.

However Sarepta Therapeutics's short interest can also be evaluated against the total number of Sarepta Therapeutics shares, or, against the total number of tradable Sarepta Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sarepta Therapeutics's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Sarepta Therapeutics shares in existence, roughly 90 shares are currently held short) or 0.1088% of the tradable shares (for every 100,000 tradable Sarepta Therapeutics shares, roughly 109 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Sarepta Therapeutics.

Find out more about how you can short Sarepta Therapeutics stock.

Sarepta Therapeutics share dividends

We're not expecting Sarepta Therapeutics to pay a dividend over the next 12 months.

Have Sarepta Therapeutics's shares ever split?

Sarepta Therapeutics's shares were split on a 1:6 basis on 11 July 2012. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sarepta Therapeutics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Sarepta Therapeutics shares which in turn could have impacted Sarepta Therapeutics's share price.

Sarepta Therapeutics share price volatility

Over the last 12 months, Sarepta Therapeutics's shares have ranged in value from as little as $68.04 up to $181.83. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sarepta Therapeutics's is 1.5494. This would suggest that Sarepta Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Sarepta Therapeutics overview

Sarepta Therapeutics, Inc. , a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. It also has a research and option agreement with Codiak BioSciences, Inc.

Frequently asked questions

What percentage of Sarepta Therapeutics is owned by insiders or institutions?
Currently 4.869% of Sarepta Therapeutics shares are held by insiders and 89.82% by institutions. How many people work for Sarepta Therapeutics?
Latest data suggests 866 work at Sarepta Therapeutics. When does the fiscal year end for Sarepta Therapeutics?
Sarepta Therapeutics's fiscal year ends in December. Where is Sarepta Therapeutics based?
Sarepta Therapeutics's address is: 215 First Street, Cambridge, MA, United States, 02142 What is Sarepta Therapeutics's ISIN number?
Sarepta Therapeutics's international securities identification number is: US8036071004 What is Sarepta Therapeutics's CUSIP number?
Sarepta Therapeutics's Committee on Uniform Securities Identification Procedures number is: 002346104